SCHEMBL10013396

SCHEMBL10013396

CNC(=O)[C@H](CO)NCc1ccccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
ALDH1A1 P00352 6/20 0.48
CYP2C19 P33261 2/20 0.47
POLB P06746 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.45
CA12 O43570 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
ALDH3A1 P30838 1/20 0.43
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29534084 0.85 ALDH1A1 (0.54) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL756835 0.85 ALDH1A1 (0.54) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL756836 0.85 ALDH1A1 (0.54) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL506480 0.81 TLR2 (0.48) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL506481 0.81 TLR2 (0.48) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL10013399 0.79 POLB (0.46) MEN1KMT2APOLBTSHRCA12
SCHEMBL10013397 0.78 ALDH1A1 (0.51) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL750949 0.77 ALDH1A1 (0.54) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL30025474 0.77 ALDH1A1 (0.54) MEN1KMT2AALDH1A1CYP2C19POLB
SCHEMBL4915175 0.77 MEN1 (0.63) MEN1KMT2AALDH1A1CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853452-B2 Compounds, their syntheses, compositions, and methods to treat cancer THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2014-10-07 US disclosed
US-20120027844-A1 COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER XAVIER UNIVERSITY OF LOUISIANA (US) 2012-02-02 US disclosed
US-20120027844-A1 COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER XAVIER UNIVERSITY OF LOUISIANA (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027844-A1 COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER SGMS1, PHOSPHO1, MCL1 MEN1 132/4885KMT2A 2371/4885ALDH1A1 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.